Please use this identifier to cite or link to this item:
https://www.arca.fiocruz.br/handle/icict/37202
Type
ArticleCopyright
Restricted access
Embargo date
2035-01-01
Sustainable Development Goals
03 Saúde e Bem-EstarCollections
Metadata
Show full item record
THERAPEUTICAL EFFECTS OF VACCINE FROM TRYPANOSOMA CRUZI AMASTIGOTE SURFACE PROTEIN 2 BY SIMULTANEOUS INOCULATION WITH LIVE PARASITES
Amastigote surface protein-2 (ASP-2)
Cardiomyocyte
Gene expression
Histopathology
Vaccine
Author
Affilliation
Universidade Federal de São Paulo. Departamento de Biociências. Santos, SP, Brasil.
Universidade Federal de São Paulo. Escola Paulista de Medicina. Centro de Terapia Celular e Molecular. São Paulo, SP, Brasil.
Fundação Oswaldo Cruz. Instituto René Rachou. Belo Horizonte, MG, Brasil.
Universidade Federal de Minas Gerais. Belo Horizonte, MG, Brasil.
Universidade Federal de São Paulo. Departamento de Biociências. Santos, SP, Brasil.
Universidade Federal de São Paulo. Departamento de Biociências. Santos, SP, Brasil.
Universidade Federal de São Paulo. Departamento de Biociências. Santos, SP, Brasil.
Universidade Federal de São Paulo. Departamento de Biociências. Santos, SP, Brasil.
Universidade Federal de São Paulo. Escola Paulista de Medicina. Centro de Terapia Celular e Molecular. São Paulo, SP, Brasil.
Fundação Oswaldo Cruz. Instituto René Rachou. Belo Horizonte, MG, Brasil.
Universidade Federal de Minas Gerais. Belo Horizonte, MG, Brasil.
Universidade Federal de São Paulo. Departamento de Biociências. Santos, SP, Brasil.
Universidade Federal de São Paulo. Departamento de Biociências. Santos, SP, Brasil.
Universidade Federal de São Paulo. Departamento de Biociências. Santos, SP, Brasil.
Universidade Federal de São Paulo. Departamento de Biociências. Santos, SP, Brasil.
Abstract
The aim of this study was to evaluate the efficacy of vaccine using replication-deficient human recombinant Type 5 replication-defective adenoviruses (AdHu5) carrying sequences of the amastigote surface protein 2 (ASP2) (AdASP2) in mice infected with the Trypanosoma cruzi ( T cruzi) Y strain. A total of 16 A/Sn mice female were distributed into four groups, as follows (n = 4 per group): Group 1 - Control Group (CTRL); Group 2 - Infected Group (TC): animals were infected by subcutaneous route with 150 bloodstream trypomastigotes of T cruzi Y strain; Group 3 - Immunized Group (AdASP-2): animals were immunized by intramuscular injection (im) route with 50 µL of AdSP-2 (2 × 10 8 plaque forming units [pfu]/cam) at day 0; Group 4-Immunized and Infected Group (AdASP-2+TC): animals were immunized by im route with 50 µL of ASP-2 (2 × 10 8 pfu/cam) and infected by T cruzi at the same day (day 0). It was observed a significant decrease of nests in the group that was immunized with AdASP-2 and infected on the same day. Tumor necrosis factor alpha (TNF-α) and inducible nitric oxide synthase (iNOS) gene expressions showed a significant increase in the AdASP-2+TC group when compared to TC group, but it was noted that Cyclooxygenase-2 (Cox-2) was increased in TC group when compared to AdASP-2+TC group. Increase of matrix metalloproteinases-2 (MMP-2) and decrease of MMP-9 immunoexpression in the AdASP-2+TC group was noticed as well. Oxidative DNA damage was present in myocardium for AdASP-2+TC group as a result of 8-hydroxydeoxyguanosine immunoexpression. Taken together, our results highlighted an increased oxidative stress, MMP-2 activity and inflammatory host response promoted by AdASP-2 against T cruzi infection.
Keywords
Trypanosoma cruzi (T cruzi)Amastigote surface protein-2 (ASP-2)
Cardiomyocyte
Gene expression
Histopathology
Vaccine
Share